Ernexa Therapeutics (ERNA) Stock Price, News & Analysis

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.32 to $2.59
• 50-Day Range: $2.29 to $3.72
• 52-Week Range: $2.08 to $39.38
• Volume: 97,979 shs
• Average Volume: 192,253 shs
• Market Capitalization: $10.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Ernexa Therapeutics Stock Analysis - MarketRank™

Ernexa Therapeutics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ernexa Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Ernexa Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ernexa Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ernexa Therapeutics has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.45% of the float of Ernexa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ernexa Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ernexa Therapeutics has recently decreased by 26.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ernexa Therapeutics does not currently pay a dividend.

Dividend Growth

Ernexa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.45% of the float of Ernexa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Ernexa Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ernexa Therapeutics has recently decreased by 26.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.18

News Sentiment

Ernexa Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ernexa Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.49% of the stock of Ernexa Therapeutics is held by insiders.

Percentage Held by Institutions

70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ERNA Stock Analysis - Frequently Asked Questions

How have ERNA shares performed this year?

Ernexa Therapeutics' stock was trading at $4.41 on January 1st, 2025. Since then, ERNA shares have decreased by 42.6% and is now trading at $2.53.
View the best growth stocks for 2025 here.

How were Ernexa Therapeutics' earnings last quarter?

Ernexa Therapeutics Inc. (NASDAQ:ERNA) announced its earnings results on Tuesday, November, 12th. The company reported ($73.80) EPS for the quarter. The company had revenue of $0.49 million for the quarter.

When did Ernexa Therapeutics' stock split?

Ernexa Therapeutics's stock reverse split on Thursday, June 12th 2025. The 1-15 reverse split was announced on Tuesday, June 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Ernexa Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ernexa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 6/18/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ERNA
• CIK: 748592
• Web: www.brooklynitx.com
• Phone: (212) 582-1199
• Fax: 760-438-3505
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.54 million
• Net Margins: -7,652.75%
• Pretax Margin: -8,609.35%
• Return on Equity: N/A
• Return on Assets: -285.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $580 thousand
• Price / Sales: 18.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 5.06

Miscellaneous

• Outstanding Shares: 4,160,000
• Free Float: 3,973,000
• Market Cap: $10.52 million
• Optionable: No Data
• Beta: 5.55